We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




SIDS Blood Test Could Identify At-Risk Babies

By LabMedica International staff writers
Posted on 27 Jan 2025
Print article
Image: The new discovery by researchers could predict SIDS in newborns (Photo courtesy of 123RF)
Image: The new discovery by researchers could predict SIDS in newborns (Photo courtesy of 123RF)

Sudden infant death syndrome (SIDS) remains the leading cause of death in babies between one month and one year old, with its causes largely unexplained. Researchers have now discovered blood markers linked to SIDS, paving the way for potential tests to identify infants at risk and contributing to understanding the underlying causes of the condition.

Researchers from the University of Virginia School of Medicine (Charlottesville, VA, USA) analyzed blood serum samples from infants who died of SIDS, identifying specific biological indicators that could help identify warning signs in babies and potentially save lives. In their study, the team examined 828 different metabolites involved in processes like nerve cell communication, stress response, and hormone regulation. These processes could contribute to SIDS.

The researchers found variations in certain fats, specifically sphingomyelins, which are vital for brain and lung development. These differences could disrupt these processes, potentially increasing the risk of SIDS in some infants. After adjusting for factors like age, sex, race, and ethnicity, they identified 35 biomarkers of SIDS, including ornithine—a substance critical for ammonia disposal in urine—and a lipid metabolite linked to brain and lung health. This lipid metabolite is also considered a potential indicator for fetal heart defects.

“The results of this study are very exciting – we are getting closer to explaining the pathways leading to a SIDS death,” said Dr. Fern R. Hauck, a family medicine physician at UVA Health, director of the Chicago Infant Mortality Study and a leading expert on SIDS. “Our hope is that this research lays the groundwork to help identify – through simple blood tests – infants who are at higher risk for SIDS and to save these precious lives.”

Related Links:
UVA School of Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.